Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
05 déc. 2024 08h30 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of...
Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago
17 oct. 2024 08h29 HE
|
Alkeus Pharmaceuticals
Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day Positive Data from TEASE...
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
02 juil. 2024 08h30 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer.
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
29 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. today announced that Eric L. Trachtenberg, J.D., M.B.A., has joined the company as Chief Legal Officer.
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
08 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
22 févr. 2024 16h05 HE
|
Ocugen
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
21 déc. 2023 08h00 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive...
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
03 nov. 2023 12h00 HE
|
Alkeus Pharmaceuticals
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...
Oak Bay Biosciences Inc. Opens Equity Raise With Goal of Bringing First Treatment for Inherited Blindness to the Global Market
29 sept. 2021 07h00 HE
|
Oak Bay Biosciences
VICTORIA, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Today, Oak Bay Biosciences Inc. announced its equity crowdfunding campaign to raise $1,000,000 to generate a preclinical data package...
FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease
14 juil. 2021 07h00 HE
|
Alkeus Pharmaceuticals
Only drug to receive Breakthrough Therapy Designation for Stargardt DiseaseAlkeus Pharmaceuticals to discuss next steps toward filing an NDA with the FDAOngoing clinical trial of ALK-001 in dry...